E-viri
Recenzirano
Odprti dostop
-
Turrisi, Andrew T; Kim, Kyungmann; Blum, Ronald; Sause, William T; Livingston, Robert B; Komaki, Ritsuko; Wagner, Henry; Aisner, Seena; Johnson, David H
New England journal of medicine/The New England journal of medicine, 01/1999, Letnik: 340, Številka: 4Journal Article
Of the approximately 170,000 cases of lung cancer diagnosed each year in the United States, 20 percent are small-cell cancers. 1 Staging systems divide small-cell lung cancer into two categories: limited and extensive. The former is clinically confined to one side of the chest and is treatable by radiotherapy field sizes (portals) tolerated by normal tissues. The main treatment for limited small-cell lung cancer is radiotherapy and chemotherapy. Cisplatin plus etoposide has largely supplanted the older regimens of cyclophosphamide, doxorubicin, and vincristine. Advantages of the cisplatin–etoposide regimen over the older regimen include the absence of toxic effects on intrathoracic organs and . . .
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|
Vir: Osebne bibliografije
in: SICRIS
To gradivo vam je dostopno v celotnem besedilu. Če kljub temu želite naročiti gradivo, kliknite gumb Nadaljuj.